首页 > 最新文献

Turkish Thoracic Journal最新文献

英文 中文
Clinical Outcome of PCR-Negative COVID-19 Patients: A Retrospective Study. pcr阴性COVID-19患者的临床结局:一项回顾性研究
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20284
Abdullah Sayıner, Mehmet Sezai Tasbakan, Begüm Ergan, Oğuz Kılınç, Arzu Sayıner, Ruchan Sertoz, Selin Ozuygur, Selin Ercan, Yusuf Savran, Pervin Korkmaz Ekren, Özen K Başoğlu, Mustafa H Özhan

Objective: To evaluate the clinical features and outcomes of patients who were admitted with a diagnosis of coronavirus disease 2019 (COVID-19) but who were not confirmed with polymerase chain reaction (PCR) positivity.

Material and methods: This is a retrospective analysis of all patients admitted to two tertiary care centers between March 15 and May 15, 2020, with a diagnosis of COVID-19. From a common database prepared for COVID-19, we retrieved the relevant data and compared the clinical findings and outcomes of PCR-positive patients with those of PCR-negative cases who had been diagnosed on the basis of typical clinical and radiographic findings.

Results: A total of 349 patients were included in the analysis, of which 126 (36.1%) were PCR-negative. PCR-negative patients were younger (54.6 ± 20.8 vs. 60.8 ± 18.9 years, P = .009) but were similar to PCR-positive patients in terms of demographics, comorbidities, and presenting symptoms. They had higher lymphocyte counts (1519 ± 868 vs. 1331 ± 737/mm3, P = .02) and less frequently presented with bilateral radiographic findings (68.3% vs. 79.4%, P = .046) than PCR-positive patients. Besides, they had less severe disease and better clinical outcomes regarding admission to the intensive care unit (9.6% vs. 20.6%, P = .023), oxygen therapy (21.4% vs. 43.5%, P < .001), ventilatory support (3.2% vs. 11.2%, P = .03) and length of hospital stay (5.0 ± 5.0 vs. 9.7 ± 5.9 days, P < .001).

Conclusion: This study confirms that about one-third of the COVID-19 patients are PCR-negative and diagnosed based on clinical and radiographic findings. These patients have a more favorable clinical course, shorter hospital stays, and are less frequently admitted to the intensive care unit.

目的:评价新冠肺炎(COVID-19)患者入院后未确诊聚合酶链反应(PCR)阳性的临床特点及转归。材料和方法:这是对2020年3月15日至5月15日期间两家三级医疗中心确诊为COVID-19的所有患者的回顾性分析。从COVID-19通用数据库中检索相关数据,将pcr阳性患者的临床表现和结局与根据典型临床和影像学表现诊断的pcr阴性病例进行比较。结果:共纳入349例患者,其中pcr阴性126例(36.1%)。pcr阴性患者较年轻(54.6±20.8岁vs 60.8±18.9岁,P = 0.009),但在人口统计学、合并症和表现症状方面与pcr阳性患者相似。淋巴细胞计数(1519±868比1331±737/mm3, P = 0.02)高于pcr阳性患者,双侧影像学表现较少(68.3%比79.4%,P = 0.046)。此外,在重症监护病房入院(9.6%比20.6%,P = 0.023)、氧疗(21.4%比43.5%,P < 0.001)、呼吸支持(3.2%比11.2%,P = 0.03)和住院时间(5.0±5.0比9.7±5.9天,P < 0.001)方面,他们的病情较轻,临床结果较好。结论:本研究证实,约三分之一的COVID-19患者为pcr阴性,并根据临床和影像学表现进行诊断。这些患者的临床病程较好,住院时间较短,并且入住重症监护病房的频率较低。
{"title":"Clinical Outcome of PCR-Negative COVID-19 Patients: A Retrospective Study.","authors":"Abdullah Sayıner,&nbsp;Mehmet Sezai Tasbakan,&nbsp;Begüm Ergan,&nbsp;Oğuz Kılınç,&nbsp;Arzu Sayıner,&nbsp;Ruchan Sertoz,&nbsp;Selin Ozuygur,&nbsp;Selin Ercan,&nbsp;Yusuf Savran,&nbsp;Pervin Korkmaz Ekren,&nbsp;Özen K Başoğlu,&nbsp;Mustafa H Özhan","doi":"10.5152/TurkThoracJ.2021.20284","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20284","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical features and outcomes of patients who were admitted with a diagnosis of coronavirus disease 2019 (COVID-19) but who were not confirmed with polymerase chain reaction (PCR) positivity.</p><p><strong>Material and methods: </strong>This is a retrospective analysis of all patients admitted to two tertiary care centers between March 15 and May 15, 2020, with a diagnosis of COVID-19. From a common database prepared for COVID-19, we retrieved the relevant data and compared the clinical findings and outcomes of PCR-positive patients with those of PCR-negative cases who had been diagnosed on the basis of typical clinical and radiographic findings.</p><p><strong>Results: </strong>A total of 349 patients were included in the analysis, of which 126 (36.1%) were PCR-negative. PCR-negative patients were younger (54.6 ± 20.8 vs. 60.8 ± 18.9 years, P = .009) but were similar to PCR-positive patients in terms of demographics, comorbidities, and presenting symptoms. They had higher lymphocyte counts (1519 ± 868 vs. 1331 ± 737/mm3, P = .02) and less frequently presented with bilateral radiographic findings (68.3% vs. 79.4%, P = .046) than PCR-positive patients. Besides, they had less severe disease and better clinical outcomes regarding admission to the intensive care unit (9.6% vs. 20.6%, P = .023), oxygen therapy (21.4% vs. 43.5%, P < .001), ventilatory support (3.2% vs. 11.2%, P = .03) and length of hospital stay (5.0 ± 5.0 vs. 9.7 ± 5.9 days, P < .001).</p><p><strong>Conclusion: </strong>This study confirms that about one-third of the COVID-19 patients are PCR-negative and diagnosed based on clinical and radiographic findings. These patients have a more favorable clinical course, shorter hospital stays, and are less frequently admitted to the intensive care unit.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"247-250"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975318/pdf/ttj-22-3-247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Endosonography Diagnosis with a New ProCore 20G of Mediastinal Metastasis from a Malignant Cutaneous Melanoma. 恶性皮肤黑色素瘤纵隔转移新发原核20G的超声诊断。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20063
Samuel Galante Romanini, Arthur Ferraz de Almeida, Juliana Silveira Lima de Castro, Juan Pablo Román Serrano, Isabela Trindade Torres, José Celso Ardengh

Melanoma is an uncommon tumor and represents about 1.5% of all neoplasms. In the mediastinum, it presents as a primary neoplasm or metastasis. Diagnosis is essential for the adoption of the best therapy. Endosonography-guided fine needle aspiration (EUS-FNA) obtains cell samples and, when associated with other auxiliary exams such as immunohistochemistry, is useful to identify and differentiate primary and/or metastatic mediastinal lesions from a wide variety of other neoplasms. The endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) sensitivity is low and similar to endobronchial ultrasound-guided transbronchial needle biopsy (EBUS-TBNB) performed with the ProCore 25G or 22G needle. Thus, the diagnosis of this type of tumor becomes a great challenge. The authors report the first case in the literature of metastatic mediastinal melanoma derived from malignant cutaneous melanoma, which was submitted to Endosonography-guided fine needle biopsy (EUS-FNB) with the new ProCore 20G, to obtain tissue, being confirmed by histological examination of the specimens obtained with a single puncture.

黑色素瘤是一种罕见的肿瘤,约占所有肿瘤的1.5%。在纵隔,它表现为原发性肿瘤或转移灶。诊断对于采用最佳治疗方法至关重要。超声引导下细针穿刺(EUS-FNA)获取细胞样本,当与其他辅助检查(如免疫组织化学)相结合时,可用于识别和区分原发性和/或转移性纵隔病变与各种其他肿瘤。超声引导下支气管穿刺穿刺(EBUS-TBNA)的敏感性较低,与超声引导下使用ProCore 25G或22G针进行的支气管穿刺活检(EBUS-TBNB)相似。因此,这类肿瘤的诊断成为一个巨大的挑战。作者报告了文献中第一例来自恶性皮肤黑色素瘤的转移性纵隔黑色素瘤,该病例采用新型ProCore 20G进行内窥镜引导下细针活检(EUS-FNB)获取组织,并通过单次穿刺获得的标本进行组织学检查。
{"title":"Endosonography Diagnosis with a New ProCore 20G of Mediastinal Metastasis from a Malignant Cutaneous Melanoma.","authors":"Samuel Galante Romanini,&nbsp;Arthur Ferraz de Almeida,&nbsp;Juliana Silveira Lima de Castro,&nbsp;Juan Pablo Román Serrano,&nbsp;Isabela Trindade Torres,&nbsp;José Celso Ardengh","doi":"10.5152/TurkThoracJ.2021.20063","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20063","url":null,"abstract":"<p><p>Melanoma is an uncommon tumor and represents about 1.5% of all neoplasms. In the mediastinum, it presents as a primary neoplasm or metastasis. Diagnosis is essential for the adoption of the best therapy. Endosonography-guided fine needle aspiration (EUS-FNA) obtains cell samples and, when associated with other auxiliary exams such as immunohistochemistry, is useful to identify and differentiate primary and/or metastatic mediastinal lesions from a wide variety of other neoplasms. The endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) sensitivity is low and similar to endobronchial ultrasound-guided transbronchial needle biopsy (EBUS-TBNB) performed with the ProCore 25G or 22G needle. Thus, the diagnosis of this type of tumor becomes a great challenge. The authors report the first case in the literature of metastatic mediastinal melanoma derived from malignant cutaneous melanoma, which was submitted to Endosonography-guided fine needle biopsy (EUS-FNB) with the new ProCore 20G, to obtain tissue, being confirmed by histological examination of the specimens obtained with a single puncture.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"267-270"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449892/pdf/ttj-22-3-267.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compassion Fatigue in Chest Disease Clinicians: The Effect of Psychological Capital and the Relationship between Colleagues. 胸病临床医生同情疲劳:心理资本的影响及同事关系。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20160
Hanife Salur, Nazmiye Yıldırım

Objective: Compassion fatigue is representative of the cost of caring and is reported to have significant negative effects. Compassion fatigue needs to be better understood in order to define, prevent, and intervene. The aim of this study is to determine the level of compassion fatigue and possible predictors (demographics, vocational features, satisfaction, and psychological capital) in physicians and nurses working in chest diseases and thoracic surgery hospital.

Material and methods: This cross-sectional study was conducted with 205 clinicians (83 physicians, 122 nurses) working face-toface with in-patients. Data were collected with a semi-structured interview, the Professional Quality of Life Scale, and the Psychological Capital Scale.

Results: The average age of the participants was 31.96 ± 8.60 years, most of them (67.3%) were women. The average compassion fatigue score was 20.15 ± 8.58 for the physicians and 17.16 ± 9.49 for the nurses, and the difference was found to be statistically significant (P = .01). However, in the regression analysis, it was determined that the profession did not have a significant effect, and that dissatisfaction with the colleagues increased the compassion fatigue 2.5-fold (P = .03). It was found that low resilience, one of the subscales of the Psychological Capital Scale, increased compassion fatigue 2.14-fold (P = .007). Other professional variables and demographic characteristics were not significantly related to compassion fatigue (P > .05).

Conclusion: The results of this study show the importance of the relationship and resilience among colleagues in the prevention of compassion fatigue. It also points out that physicians are at risk of developing compassion fatigue.

目的:同情疲劳是关怀成本的代表,并被报道具有显著的负面影响。同情疲劳需要更好地理解,以便定义、预防和干预。本研究的目的是确定在胸外科医院工作的医生和护士的同情疲劳水平和可能的预测因素(人口统计学、职业特征、满意度和心理资本)。材料和方法:本横断面研究由205名临床医生(83名内科医生,122名护士)与住院病人面对面进行。数据收集采用半结构化访谈、职业生活质量量表和心理资本量表。结果:参与者的平均年龄为31.96±8.60岁,以女性居多(67.3%)。医师的同情疲劳平均得分为20.15±8.58分,护士的同情疲劳平均得分为17.16±9.49分,差异有统计学意义(P = 0.01)。然而,在回归分析中,确定职业没有显著影响,对同事的不满使同情疲劳增加2.5倍(P = .03)。研究发现,低弹性(心理资本量表的一个子量表)增加了2.14倍的同情疲劳(P = 0.007)。其他职业变量和人口学特征与同情疲劳无显著相关(P > 0.05)。结论:本研究结果显示同事之间的关系和弹性在预防同情疲劳中的重要性。它还指出,医生有患上同情疲劳的风险。
{"title":"Compassion Fatigue in Chest Disease Clinicians: The Effect of Psychological Capital and the Relationship between Colleagues.","authors":"Hanife Salur,&nbsp;Nazmiye Yıldırım","doi":"10.5152/TurkThoracJ.2021.20160","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20160","url":null,"abstract":"<p><strong>Objective: </strong>Compassion fatigue is representative of the cost of caring and is reported to have significant negative effects. Compassion fatigue needs to be better understood in order to define, prevent, and intervene. The aim of this study is to determine the level of compassion fatigue and possible predictors (demographics, vocational features, satisfaction, and psychological capital) in physicians and nurses working in chest diseases and thoracic surgery hospital.</p><p><strong>Material and methods: </strong>This cross-sectional study was conducted with 205 clinicians (83 physicians, 122 nurses) working face-toface with in-patients. Data were collected with a semi-structured interview, the Professional Quality of Life Scale, and the Psychological Capital Scale.</p><p><strong>Results: </strong>The average age of the participants was 31.96 ± 8.60 years, most of them (67.3%) were women. The average compassion fatigue score was 20.15 ± 8.58 for the physicians and 17.16 ± 9.49 for the nurses, and the difference was found to be statistically significant (P = .01). However, in the regression analysis, it was determined that the profession did not have a significant effect, and that dissatisfaction with the colleagues increased the compassion fatigue 2.5-fold (P = .03). It was found that low resilience, one of the subscales of the Psychological Capital Scale, increased compassion fatigue 2.14-fold (P = .007). Other professional variables and demographic characteristics were not significantly related to compassion fatigue (P > .05).</p><p><strong>Conclusion: </strong>The results of this study show the importance of the relationship and resilience among colleagues in the prevention of compassion fatigue. It also points out that physicians are at risk of developing compassion fatigue.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"205-211"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975335/pdf/ttj-22-3-205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39579369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Surgical Treatment in Small-Cell Lung Cancer: Single-Center Experience and Survival. 小细胞肺癌的手术治疗:单中心经验和生存率。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.19140
Ahmet Ulusan, İbrahim Emre Tunca, Maruf Şanlı, Ahmet Feridun Işık

Objective: To evaluate the clinical outcomes of patients with different stages of small-cell lung cancer (SCLC) who underwent surgical treatment.

Material and methods: This retrospective study consisted of 13 patients with SCLC at a tertiary care health center. This study was conducted between 2011 and 2018 at Gaziantep University Faculty of Medicine, Thoracic Surgery Department. Patient follow-up data were collected from medical files. Patients were analyzed according to age, sex, site of resection, clinical stage, pathological stage, recurrence, operation type, chemotherapy, radiotherapy.

Results: The study group consisted of 3 females and 10 males (n = 13). The mean age of the patients was 65 ± 9.3 (52-85) years. The most common location of the primary tumor was the right upper lobe (6 patients, 46.2%). The mean tumor size was 4.36 ± 2.38 cm (1-8.5). In our study, 3 patients had already metastases (2 brain and 1 had metastases in more than 2 anatomic sites). Patients with solitary metastases, who underwent lung resection and metastasis excision had similar survival according to patients without metastases.

Conclusion: Our results show that surgical treatment in SCLC could be contributed to the survival of patients. Therefore, patients must be given a chance for surgery, especially considering that the advances in diagnostic and surgical capabilities have increased the likelihood of early diagnosis and effective surgery.

目的:探讨不同分期小细胞肺癌(SCLC)手术治疗的临床效果。材料和方法:本回顾性研究包括一家三级保健中心的13例SCLC患者。这项研究于2011年至2018年在加济安泰普大学医学院胸外科进行。患者随访数据从医疗档案中收集。根据患者的年龄、性别、切除部位、临床分期、病理分期、复发情况、手术类型、化疗、放疗进行分析。结果:研究组女性3例,男性10例(n = 13)。患者平均年龄65±9.3(52 ~ 85)岁。原发肿瘤最常见的部位为右上叶(6例,46.2%)。肿瘤平均大小为4.36±2.38 cm(1 ~ 8.5)。在我们的研究中,3例患者已经发生转移(2例脑转移,1例超过2个解剖部位转移)。孤立性转移患者行肺切除和转移切除的生存率与无转移患者相似。结论:我们的研究结果表明,手术治疗可以促进SCLC患者的生存。因此,必须给予患者手术的机会,特别是考虑到诊断和手术能力的进步增加了早期诊断和有效手术的可能性。
{"title":"Surgical Treatment in Small-Cell Lung Cancer: Single-Center Experience and Survival.","authors":"Ahmet Ulusan,&nbsp;İbrahim Emre Tunca,&nbsp;Maruf Şanlı,&nbsp;Ahmet Feridun Işık","doi":"10.5152/TurkThoracJ.2021.19140","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.19140","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical outcomes of patients with different stages of small-cell lung cancer (SCLC) who underwent surgical treatment.</p><p><strong>Material and methods: </strong>This retrospective study consisted of 13 patients with SCLC at a tertiary care health center. This study was conducted between 2011 and 2018 at Gaziantep University Faculty of Medicine, Thoracic Surgery Department. Patient follow-up data were collected from medical files. Patients were analyzed according to age, sex, site of resection, clinical stage, pathological stage, recurrence, operation type, chemotherapy, radiotherapy.</p><p><strong>Results: </strong>The study group consisted of 3 females and 10 males (n = 13). The mean age of the patients was 65 ± 9.3 (52-85) years. The most common location of the primary tumor was the right upper lobe (6 patients, 46.2%). The mean tumor size was 4.36 ± 2.38 cm (1-8.5). In our study, 3 patients had already metastases (2 brain and 1 had metastases in more than 2 anatomic sites). Patients with solitary metastases, who underwent lung resection and metastasis excision had similar survival according to patients without metastases.</p><p><strong>Conclusion: </strong>Our results show that surgical treatment in SCLC could be contributed to the survival of patients. Therefore, patients must be given a chance for surgery, especially considering that the advances in diagnostic and surgical capabilities have increased the likelihood of early diagnosis and effective surgery.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"237-241"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975300/pdf/ttj-22-3-237.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Providing Free Access to Smoking Cessation Medications: Does It Have an Impact on the Treatment Adherence and Success of Smoking Cessation? 免费提供戒烟药物:对治疗依从性和戒烟成功有影响吗?
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20124
Olesya Aksel, Nevin Küçüktepe, Zafer Yaslıca, Okay Başak

Objective: Providing medications to patients free of charge is thought to be one of the factors affecting the success of smoking cessation. The aim of this study was to investigate the effect of providing free access to stop-smoking medications on the treatment adherence and short term success of quitting smoking.

Material and methods: All smokers who applied to a smoking cessation outpatient clinic between September 2017 and December 2019 were included in this retrospective study. Data were collected from patients' files filled using an initial evaluation and follow-up protocol.

Results: During the study period, 518 smokers applied to our polyclinic for smoking cessation counseling. Medical therapy was prescribed for 411 (85.4%) of 481 patients who were supported by behavioral therapy. The patients had a mean age of 41.2 years, and 64.7% were male. Only 22.9% of smokers prescribed stop-smoking medications were able to obtain them for free. Patients who got the medications completely free of charge were 4 times more adherent to treatment. The success rate of quitting smoking at the end of the third month was 22.2%. The strongest effect was achieved by the full treatment compliance. At the end of 3 months, the success of quitting smoking was 14.1 times higher for those who were fully adherent to treatment than non-adherents.

Discussion: According to our study results, the most effective success factors in short-term smoking cessation are patient compliance to treatment and free supply of stop-smoking medications, one of the main determinants of treatment adherence.

目的:向患者免费提供药物被认为是影响戒烟成功的因素之一。本研究的目的是调查免费提供戒烟药物对治疗依从性和短期戒烟成功的影响。材料和方法:2017年9月至2019年12月期间申请戒烟门诊诊所的所有吸烟者均纳入本回顾性研究。数据收集自使用初始评估和随访方案填写的患者档案。结果:在研究期间,518名吸烟者向我们的综合诊所申请戒烟咨询。481例患者中有411例(85.4%)在行为治疗的支持下进行药物治疗。患者平均年龄41.2岁,男性占64.7%。只有22.9%的吸烟者能够免费获得开出的戒烟药物。完全免费服用药物的患者坚持治疗的几率是前者的4倍。第三个月末戒烟成功率为22.2%。完全的治疗依从性达到了最强的效果。3个月后,完全坚持治疗的人的戒烟成功率是不坚持治疗的人的14.1倍。讨论:根据我们的研究结果,短期戒烟最有效的成功因素是患者对治疗的依从性和免费提供戒烟药物,这是治疗依从性的主要决定因素之一。
{"title":"Providing Free Access to Smoking Cessation Medications: Does It Have an Impact on the Treatment Adherence and Success of Smoking Cessation?","authors":"Olesya Aksel,&nbsp;Nevin Küçüktepe,&nbsp;Zafer Yaslıca,&nbsp;Okay Başak","doi":"10.5152/TurkThoracJ.2021.20124","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20124","url":null,"abstract":"<p><strong>Objective: </strong>Providing medications to patients free of charge is thought to be one of the factors affecting the success of smoking cessation. The aim of this study was to investigate the effect of providing free access to stop-smoking medications on the treatment adherence and short term success of quitting smoking.</p><p><strong>Material and methods: </strong>All smokers who applied to a smoking cessation outpatient clinic between September 2017 and December 2019 were included in this retrospective study. Data were collected from patients' files filled using an initial evaluation and follow-up protocol.</p><p><strong>Results: </strong>During the study period, 518 smokers applied to our polyclinic for smoking cessation counseling. Medical therapy was prescribed for 411 (85.4%) of 481 patients who were supported by behavioral therapy. The patients had a mean age of 41.2 years, and 64.7% were male. Only 22.9% of smokers prescribed stop-smoking medications were able to obtain them for free. Patients who got the medications completely free of charge were 4 times more adherent to treatment. The success rate of quitting smoking at the end of the third month was 22.2%. The strongest effect was achieved by the full treatment compliance. At the end of 3 months, the success of quitting smoking was 14.1 times higher for those who were fully adherent to treatment than non-adherents.</p><p><strong>Discussion: </strong>According to our study results, the most effective success factors in short-term smoking cessation are patient compliance to treatment and free supply of stop-smoking medications, one of the main determinants of treatment adherence.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"224-230"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975362/pdf/ttj-22-3-224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Primary Pulmonary Marginal Cell Lymphoma: Your Eyes See Only What Your Mind Knows. 原发性肺边缘细胞淋巴瘤:你的眼睛只看到你的大脑所知道的。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20008
Aqeel Hussain, Rajkrishman Soman, Abhishek Goyal, Ujjawal Khurana, Sheetal Malpani, Surbhi Lahoti, Alkesh Khurana

Lung cancer is the leading cause of cancer-associated mortality, with a 5-year survival of 19% for all types of lung cancer. Lymphoid malignancies of the lung have a significantly better prognosis, with 5-year survival approaching 90%, making it very important to identify these patients. As the signs and symptoms, laboratory investigations, and radiological features are non-specific and vague and the histological confirmation is invasive, they are usually either not diagnosed or diagnosed very late. We present a case of an elderly male who was treated for months with antituberculosis treatment (ATT) before being properly evaluated and diagnosed with primary pulmonary marginal cell lymphoma. This case was unique for having gross pleural effusion as a presenting feature and having been diagnosed with the help of radial endobronchial ultrasound (EBUS).

肺癌是癌症相关死亡的主要原因,所有类型肺癌的5年生存率为19%。肺部淋巴细胞恶性肿瘤的预后明显较好,其5年生存率接近90%,因此鉴别这些患者非常重要。由于体征和症状、实验室检查和放射学特征不特异性和模糊,组织学证实是侵入性的,因此通常未被诊断或诊断得很晚。我们提出一个老年男性的病例,他接受了几个月的抗结核治疗(ATT),然后被适当地评估和诊断为原发性肺边缘细胞淋巴瘤。这个病例是独特的,以胸膜积液为表现特征,并在径向支气管内超声(EBUS)的帮助下诊断。
{"title":"Primary Pulmonary Marginal Cell Lymphoma: Your Eyes See Only What Your Mind Knows.","authors":"Aqeel Hussain,&nbsp;Rajkrishman Soman,&nbsp;Abhishek Goyal,&nbsp;Ujjawal Khurana,&nbsp;Sheetal Malpani,&nbsp;Surbhi Lahoti,&nbsp;Alkesh Khurana","doi":"10.5152/TurkThoracJ.2021.20008","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20008","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-associated mortality, with a 5-year survival of 19% for all types of lung cancer. Lymphoid malignancies of the lung have a significantly better prognosis, with 5-year survival approaching 90%, making it very important to identify these patients. As the signs and symptoms, laboratory investigations, and radiological features are non-specific and vague and the histological confirmation is invasive, they are usually either not diagnosed or diagnosed very late. We present a case of an elderly male who was treated for months with antituberculosis treatment (ATT) before being properly evaluated and diagnosed with primary pulmonary marginal cell lymphoma. This case was unique for having gross pleural effusion as a presenting feature and having been diagnosed with the help of radial endobronchial ultrasound (EBUS).</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"271-273"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975319/pdf/ttj-22-3-271.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39882301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Can the Usage of the Chest X-Ray Scoring During Hospitalization in Patients with COVID-19 Predict the Severity of the Disease? COVID-19患者住院期间胸片评分能否预测病情严重程度?
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.21025
Selma Aydoğan Eroğlu, Zeynep Çagavi, Tekin Yıldız, Zuhal Karakurt, On Behalf Of Covid Interest Group

Objective: The prevalence of radiological involvement is considered a poor prognostic factor for coronavirus disease 2019 (COVID- 19). In our study, we aimed to investigate the threshold value of the chest X-ray (CXR) score, which would require the patient to be transferred to the intensive care unit (ICU) through scoring the CXR of COVID-19 patients receiving in-patient treatment.

Material and methods: The patients that tested positive for COVID-19 on the basis of the polymerase chain reaction (PCR) test, who was hospitalized in our hospital between the dates of March 15 and May 30, 2020, were included in the study. The CXRs of these patients taken during hospitalization were scored. The threshold value of the CXR score of the patients transferred to the ICU was calculated. Patients were grouped according to the threshold value of the CXR score, and demographic data and other recorded parameters were compared.

Results: A total of 301 patients were included in this retrospective cross-sectional study. It was determined that finding of a CXR score threshold value of 5 or above during hospitalization predicted a transfer to the ICU with 90% sensitivity and 80% specificity. The use of broad-spectrum antibiotics, the laboratory parameters (leukocyte, neutrophil, C-reactive protein (CRP), procalcitonin, troponin, D-dimer, ferritin), and rate of transfer to ICU were found to be significantly higher in the group with a CXR score of 5 and above, compared to the group with CXR score below 5 (P < .001 in each).

Conclusion: Finding high CXR scores during hospitalization due to COVID-19 may act as a warning in terms of the severity of the disease. It may be beneficial to examine the chest X-ray images during hospitalization with utmost care and take these images into account.

目的:影像学受累的流行被认为是冠状病毒病2019 (COVID- 19)预后不良的因素。在我们的研究中,我们旨在通过对住院治疗的COVID-19患者的胸部x线(CXR)评分,探讨需要患者转入重症监护病房(ICU)的阈值。材料与方法:选取2020年3月15日至5月30日在我院住院的新型冠状病毒肺炎聚合酶链反应(PCR)检测呈阳性的患者。对这些患者住院期间的cxr进行评分。计算转ICU患者的CXR评分阈值。根据CXR评分阈值对患者进行分组,比较人口学资料及其他记录参数。结果:本回顾性横断面研究共纳入301例患者。我们确定,住院期间发现CXR评分阈值为5或以上,预测转至ICU的敏感性为90%,特异性为80%。广谱抗生素的使用、实验室指标(白细胞、中性粒细胞、c反应蛋白(CRP)、降钙素原、肌钙蛋白、d-二聚体、铁蛋白)、转ICU率在CXR评分为5分及以上组明显高于CXR评分为5分以下组(P < 0.001)。结论:在COVID-19住院期间发现高的CXR评分可能对疾病的严重程度起到警示作用。在住院期间仔细检查胸部x线图像并考虑这些图像可能是有益的。
{"title":"Can the Usage of the Chest X-Ray Scoring During Hospitalization in Patients with COVID-19 Predict the Severity of the Disease?","authors":"Selma Aydoğan Eroğlu,&nbsp;Zeynep Çagavi,&nbsp;Tekin Yıldız,&nbsp;Zuhal Karakurt,&nbsp;On Behalf Of Covid Interest Group","doi":"10.5152/TurkThoracJ.2021.21025","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.21025","url":null,"abstract":"<p><strong>Objective: </strong>The prevalence of radiological involvement is considered a poor prognostic factor for coronavirus disease 2019 (COVID- 19). In our study, we aimed to investigate the threshold value of the chest X-ray (CXR) score, which would require the patient to be transferred to the intensive care unit (ICU) through scoring the CXR of COVID-19 patients receiving in-patient treatment.</p><p><strong>Material and methods: </strong>The patients that tested positive for COVID-19 on the basis of the polymerase chain reaction (PCR) test, who was hospitalized in our hospital between the dates of March 15 and May 30, 2020, were included in the study. The CXRs of these patients taken during hospitalization were scored. The threshold value of the CXR score of the patients transferred to the ICU was calculated. Patients were grouped according to the threshold value of the CXR score, and demographic data and other recorded parameters were compared.</p><p><strong>Results: </strong>A total of 301 patients were included in this retrospective cross-sectional study. It was determined that finding of a CXR score threshold value of 5 or above during hospitalization predicted a transfer to the ICU with 90% sensitivity and 80% specificity. The use of broad-spectrum antibiotics, the laboratory parameters (leukocyte, neutrophil, C-reactive protein (CRP), procalcitonin, troponin, D-dimer, ferritin), and rate of transfer to ICU were found to be significantly higher in the group with a CXR score of 5 and above, compared to the group with CXR score below 5 (P < .001 in each).</p><p><strong>Conclusion: </strong>Finding high CXR scores during hospitalization due to COVID-19 may act as a warning in terms of the severity of the disease. It may be beneficial to examine the chest X-ray images during hospitalization with utmost care and take these images into account.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"190-198"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975310/pdf/ttj-22-3-190.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39579367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. 大剂量雾化干扰素α 2b治疗重症COVID-19肺炎的疗效观察
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20255
Ayman Chkhis, Najiba Abdulrazzaq, Sherif Mokhtar, Alia Al Jasmi

Objective: The COVID-19 pandemic is progressing rapidly, sending the world into a great panic. Healthcare professionals have responded by embarking on a concerted search for therapies to cure and prevent COVID-19. Recently, interferon (IFN) has emerged as a potential therapy as it is associated with reducing lung inflammation and suppressing viral replication. This research paper assessed the efficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.

Methods: This is a retrospective study. It commenced on April 9 and ended on June 17, 2020. Researchers selected participants from hospitalized patients aged 18 years and above who were diagnosed with severe COVID-19 pneumonia. Other inclusion criteria were bilateral pneumonia on lung or chest X-ray scan and severe respiratory distress. SMART-COP, which is a risk stratification scoring tool, and radiologic severity index (RSI) were used to assess pneumonia severity. Patients in the treatment cohort received nebulized IFN α 2b at a dose of 10 million IU every 12 hours for 5 days, in addition to standard treatment. Patients in the control cohort received standard treatment only.

Results: Seventy-three patients met the inclusion criteria; 37 were included in the treatment cohort and 36 in the control cohort. Mechanical ventilation was needed in 14 of 36 (38.9%) patients in the control cohort, compared with 6 of 37 (27.4%) patients in the treatment cohort (HR 5.62 [95% CI 1.81-17.48]; P = .003). For pneumonia severity, there was a hazard ratio (HR) of 3.72 [95% CI 1.74- 7.98]; P = ·.01. After 5 days of treatment, chest X-rays indicated significant beneficial changes in the treatment group (HR 2.24 [CI 1.05-4.79]; P = .036). Multivariate analysis revealed that pneumonia severity and RSI remained higher in the control group. The HR was 3.44 [95% CI 1.49-7.94]; P = .004 and 2.26 [95% CI 0.99-5.16]; P = .05, respectively. There was an increase in liver aminotransferases in 5 (14%) participants in the control cohort and 3 (8%) participants in the treatment cohort.

Conclusion: High-dose nebulized IFN α 2b has potential efficacy in mitigating severe COVID-19 pneumonia. This study established that administering high-dose nebulized IFN α 2b significantly reduces pneumonia severity in COVID-19 patients. We also found a strong relationship between using nebulized IFN α 2b and reduced need for mechanical ventilation among patients with severe COVID-19 pneumonia. However, a well-designed control trial is needed to confirm the drug's efficacy in reducing the COVID-19 pneumonia severity.

目的:当前新冠肺炎疫情快速蔓延,全球陷入巨大恐慌。医疗保健专业人员已经开始协调一致地寻找治疗和预防COVID-19的疗法。最近,干扰素(IFN)已成为一种潜在的治疗方法,因为它与减少肺部炎症和抑制病毒复制有关。本研究评价了大剂量雾化IFN α 2b治疗COVID-19重症肺炎的疗效。方法:回顾性研究。从2020年4月9日开始,到6月17日结束。研究人员从18岁及以上被诊断为COVID-19严重肺炎的住院患者中选择了参与者。其他入选标准为肺或胸部x线扫描双侧肺炎和严重呼吸窘迫。使用风险分层评分工具SMART-COP和放射严重程度指数(RSI)评估肺炎严重程度。治疗组患者在标准治疗的基础上,以每12小时1000万IU的剂量雾化IFN α 2b,持续5天。对照组患者仅接受标准治疗。结果:73例患者符合纳入标准;37人被纳入治疗组,36人被纳入对照组。对照组36例患者中有14例(38.9%)需要机械通气,而治疗组37例患者中有6例(27.4%)需要机械通气(HR 5.62 [95% CI 1.81-17.48];P = .003)。肺炎严重程度的风险比(HR)为3.72 [95% CI 1.74- 7.98];P =·0.01。治疗5天后,胸部x光片显示治疗组有明显的有益变化(HR 2.24 [CI 1.05-4.79];P = .036)。多因素分析显示,对照组的肺炎严重程度和RSI仍然较高。风险比为3.44 [95% CI 1.49 ~ 7.94];P = 0.004和2.26 [95% CI 0.99-5.16];P = 0.05。对照组中有5人(14%)肝转氨酶升高,治疗组中有3人(8%)肝转氨酶升高。结论:大剂量IFN α 2b雾化治疗COVID-19重症肺炎具有潜在疗效。本研究证实,给予大剂量雾化IFN α 2b可显著降低COVID-19患者肺炎严重程度。我们还发现,在COVID-19重症肺炎患者中,使用雾化IFN α 2b与减少机械通气需求之间存在密切关系。然而,为了证实药物降低COVID-19肺炎严重程度的有效性,需要进行精心设计的对照试验。
{"title":"Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia.","authors":"Ayman Chkhis,&nbsp;Najiba Abdulrazzaq,&nbsp;Sherif Mokhtar,&nbsp;Alia Al Jasmi","doi":"10.5152/TurkThoracJ.2021.20255","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20255","url":null,"abstract":"<p><strong>Objective: </strong>The COVID-19 pandemic is progressing rapidly, sending the world into a great panic. Healthcare professionals have responded by embarking on a concerted search for therapies to cure and prevent COVID-19. Recently, interferon (IFN) has emerged as a potential therapy as it is associated with reducing lung inflammation and suppressing viral replication. This research paper assessed the efficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.</p><p><strong>Methods: </strong>This is a retrospective study. It commenced on April 9 and ended on June 17, 2020. Researchers selected participants from hospitalized patients aged 18 years and above who were diagnosed with severe COVID-19 pneumonia. Other inclusion criteria were bilateral pneumonia on lung or chest X-ray scan and severe respiratory distress. SMART-COP, which is a risk stratification scoring tool, and radiologic severity index (RSI) were used to assess pneumonia severity. Patients in the treatment cohort received nebulized IFN α 2b at a dose of 10 million IU every 12 hours for 5 days, in addition to standard treatment. Patients in the control cohort received standard treatment only.</p><p><strong>Results: </strong>Seventy-three patients met the inclusion criteria; 37 were included in the treatment cohort and 36 in the control cohort. Mechanical ventilation was needed in 14 of 36 (38.9%) patients in the control cohort, compared with 6 of 37 (27.4%) patients in the treatment cohort (HR 5.62 [95% CI 1.81-17.48]; P = .003). For pneumonia severity, there was a hazard ratio (HR) of 3.72 [95% CI 1.74- 7.98]; P = ·.01. After 5 days of treatment, chest X-rays indicated significant beneficial changes in the treatment group (HR 2.24 [CI 1.05-4.79]; P = .036). Multivariate analysis revealed that pneumonia severity and RSI remained higher in the control group. The HR was 3.44 [95% CI 1.49-7.94]; P = .004 and 2.26 [95% CI 0.99-5.16]; P = .05, respectively. There was an increase in liver aminotransferases in 5 (14%) participants in the control cohort and 3 (8%) participants in the treatment cohort.</p><p><strong>Conclusion: </strong>High-dose nebulized IFN α 2b has potential efficacy in mitigating severe COVID-19 pneumonia. This study established that administering high-dose nebulized IFN α 2b significantly reduces pneumonia severity in COVID-19 patients. We also found a strong relationship between using nebulized IFN α 2b and reduced need for mechanical ventilation among patients with severe COVID-19 pneumonia. However, a well-designed control trial is needed to confirm the drug's efficacy in reducing the COVID-19 pneumonia severity.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"199-204"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975308/pdf/ttj-22-3-199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39579368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease. 食管扩张作为间质性肺疾病患者系统性硬化症的预测因子
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.19162
Ana Filipa Santos Duarte de Figueiredo, João Felício Costa, António P Matos, Miguel Ramalho

Objective: To determine the predictive value of esophageal dilatation as observed in high-resolution computed tomography (HRCT) for the diagnosis of systemic sclerosis (SSc) in patients with interstitial lung disease (ILD).

Methods: Our sample consisted of patients diagnosed with SSc and proven interstitial lung involvement with available HRCT exams (n = 20). Individuals with other forms of rheumatic ILD were included as a control group (n = 20). Two blinded radiologists independently reviewed the images for the presence of esophageal dilatation, measured at 3 different levels. Interobserver agreement was tested with Lin's concordance correlation coefficient (CCC). Independent t-test was used to compare maximum esophageal diameters between groups. Friedman's test was used to evaluate differences between the 3-level measurements. Receiver operating characteristic analysis was performed.

Results: There was a substantial correlation between both readers (CCC = 0.9802-0.9919). Esophageal dilatation was significantly associated with SSc (P = .0012). The optimal calculated cut-off value to differentiate SSc from other ILDs was 18.5 mm (sensitivity and specificity of 70 and 90%, respectively; area under the curve 0.819), measured 1 cm above the diaphragmatic hiatus.

Conclusion: HRCT may have a discriminative role in the presence of both ILD and esophageal dilatation for the diagnosis of SSc. Our results suggest that a cut-off value for the esophageal diameter of 18.5 mm might propose the diagnosis of SSc with reasonable confidence.

目的:探讨高分辨率计算机断层扫描(HRCT)观察到的食管扩张对间质性肺疾病(ILD)患者系统性硬化症(SSc)的预测价值。方法:我们的样本包括诊断为SSc并经HRCT检查证实肺间质受累的患者(n = 20)。其他类型的风湿性ILD患者作为对照组(n = 20)。两名盲法放射科医生独立审查了食管扩张的图像,测量了3个不同的水平。采用Lin’s一致性相关系数(CCC)检验观察者间的一致性。组间最大食管直径比较采用独立t检验。弗里德曼检验用于评估三个水平测量之间的差异。进行接收机工作特性分析。结果:两种读者之间存在显著相关(CCC = 0.9802-0.9919)。食管扩张与SSc有显著相关性(P = 0.0012)。区分SSc与其他ild的最佳计算截止值为18.5 mm(敏感性和特异性分别为70%和90%;曲线下面积0.819),在膈肌间隙上方1厘米处测量。结论:HRCT在诊断SSc时,对ILD和食管扩张均有鉴别作用。我们的研究结果表明,食管直径为18.5 mm的临界值可以合理可信地诊断SSc。
{"title":"Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease.","authors":"Ana Filipa Santos Duarte de Figueiredo,&nbsp;João Felício Costa,&nbsp;António P Matos,&nbsp;Miguel Ramalho","doi":"10.5152/TurkThoracJ.2021.19162","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.19162","url":null,"abstract":"<p><strong>Objective: </strong>To determine the predictive value of esophageal dilatation as observed in high-resolution computed tomography (HRCT) for the diagnosis of systemic sclerosis (SSc) in patients with interstitial lung disease (ILD).</p><p><strong>Methods: </strong>Our sample consisted of patients diagnosed with SSc and proven interstitial lung involvement with available HRCT exams (n = 20). Individuals with other forms of rheumatic ILD were included as a control group (n = 20). Two blinded radiologists independently reviewed the images for the presence of esophageal dilatation, measured at 3 different levels. Interobserver agreement was tested with Lin's concordance correlation coefficient (CCC). Independent t-test was used to compare maximum esophageal diameters between groups. Friedman's test was used to evaluate differences between the 3-level measurements. Receiver operating characteristic analysis was performed.</p><p><strong>Results: </strong>There was a substantial correlation between both readers (CCC = 0.9802-0.9919). Esophageal dilatation was significantly associated with SSc (P = .0012). The optimal calculated cut-off value to differentiate SSc from other ILDs was 18.5 mm (sensitivity and specificity of 70 and 90%, respectively; area under the curve 0.819), measured 1 cm above the diaphragmatic hiatus.</p><p><strong>Conclusion: </strong>HRCT may have a discriminative role in the presence of both ILD and esophageal dilatation for the diagnosis of SSc. Our results suggest that a cut-off value for the esophageal diameter of 18.5 mm might propose the diagnosis of SSc with reasonable confidence.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"231-236"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975317/pdf/ttj-22-3-231.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Adult Primary Antibody Deficiencies and the Lung. 成人一抗缺陷与肺。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.20097
Ebru Damadoğlu

Primary antibody deficiency diseases result from a genetic defect that causes misfunction of 1 or more of the immune system elements. Due to the increased awareness among physicians and the success of new treatment modalities, the number of pediatric patients reaching adult age and the number of patients diagnosed in adult age is increasing. Adult patients comprise more than half of the total cases. Primary antibody deficiencies are the most common immunodeficiency type in adults, and these may cause recurrent upper and lower respiratory tract infections and result in the development of bronchiectasis. Among non-infectious pulmonary complications, any type of interstitial lung disease may be seen; however, a special type seen in patients with common variable immunodeficiency, namely granulomatous lymphocytic interstitial lung disease, is the one most commonly investigated. Underlying or accompanying immunodeficiency may be present in patients with asthma and chronic obstructive pulmonary disease, especially if the disease requires frequent hospitalizations and/or is severe. Early diagnosis and appropriate management of primary antibody deficiency diseases in patients with respiratory symptoms are crucial to decrease complications and increase survival.

一抗缺乏症是由一种基因缺陷引起的,这种基因缺陷会导致一种或多种免疫系统元素的功能失调。由于医生意识的提高和新治疗方式的成功,达到成年年龄的儿科患者数量和成年诊断的患者数量正在增加。成年患者占总病例的一半以上。一抗缺乏是成人中最常见的免疫缺陷类型,这些可引起反复的上、下呼吸道感染并导致支气管扩张的发展。在非感染性肺部并发症中,可以看到任何类型的间质性肺疾病;然而,在常见的可变免疫缺陷患者中发现的一种特殊类型,即肉芽肿性淋巴细胞间质性肺疾病,是最常研究的一种。哮喘和慢性阻塞性肺疾病患者可能存在潜在的或伴随的免疫缺陷,特别是如果疾病需要经常住院和/或病情严重。呼吸道症状患者一抗缺乏性疾病的早期诊断和适当管理对于减少并发症和提高生存率至关重要。
{"title":"Adult Primary Antibody Deficiencies and the Lung.","authors":"Ebru Damadoğlu","doi":"10.5152/TurkThoracJ.2021.20097","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20097","url":null,"abstract":"<p><p>Primary antibody deficiency diseases result from a genetic defect that causes misfunction of 1 or more of the immune system elements. Due to the increased awareness among physicians and the success of new treatment modalities, the number of pediatric patients reaching adult age and the number of patients diagnosed in adult age is increasing. Adult patients comprise more than half of the total cases. Primary antibody deficiencies are the most common immunodeficiency type in adults, and these may cause recurrent upper and lower respiratory tract infections and result in the development of bronchiectasis. Among non-infectious pulmonary complications, any type of interstitial lung disease may be seen; however, a special type seen in patients with common variable immunodeficiency, namely granulomatous lymphocytic interstitial lung disease, is the one most commonly investigated. Underlying or accompanying immunodeficiency may be present in patients with asthma and chronic obstructive pulmonary disease, especially if the disease requires frequent hospitalizations and/or is severe. Early diagnosis and appropriate management of primary antibody deficiency diseases in patients with respiratory symptoms are crucial to decrease complications and increase survival.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"257-264"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975364/pdf/ttj-22-3-257.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Turkish Thoracic Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1